After getting hopes up, expectations on Gilead, Arcus' CD73 'dimmed' on new update
When you’ve got an alliance as hefty as the one Arcus and Gilead have, every update counts.
That’s why the companies found analysts frowning on the latest disclosure around quemliclustat, their small molecule inhibitor of CD73. Although an interim analysis from a triplet combo trial in pancreatic cancer looks “promising,” it didn’t seem that much different from chemotherapy alone — triggering a decision to wait for “more mature” progression-free survival and overall survival data before making a call.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.